Life quality as a prognostic factor for treatment success in case of metabolic-associated fatty liver disease

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Metabolic-associated fatty liver disease (MAFLD) is of significant clinical importance because it predicts adverse outcomes. It is associated with serious therapeutic challenges due to the progression of the liver process from simple steatosis to steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma and associated mortality. Furthermore, MAFLD can reduce health-related quality of life, an index, improvement of which is recognized as a priority treatment goal by European Union for chronic non-communicable diseases control. Current review highlights factors influencing life quality in MAFLD patients, the impact of liver disease severity on health-related life quality, and data on the efficacy of non-pharmacological interventions and pharmacological treatments for this important parameter.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Svetlana Turkina

Volgograd State Medical University of the Ministry of Healthcare of Russia

Хат алмасуға жауапты Автор.
Email: turkinasv@rambler.ru
ORCID iD: 0000-0002-8844-2465
SPIN-код: 8613-7280

MD, Dr. Sci. (Medicine), professor of the Department of internal medicine

Ресей, Volgograd

Әдебиет тізімі

  1. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. PMID: 32044314. https://doi.org/10.1053/j.gastro.2019.11.312
  2. Sun DQ, Targher G, Byrne CD, Wheeler DC, Wong VW, Fan JG et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386–403. PMID: 37351121. PMCID: PMC10282675. https://doi.org/10.21037/hbsn-22-421
  3. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. PMID: 38851997. https://doi.org/10.1016/j.jhep.2024.04.031
  4. Samanta A, Sen Sarma M. Metabolic dysfunction-associated steatotic liver disease: A silent pandemic. World J Hepatol. 2024;16(4):511–16. PMID: 38689742. PMCID: PMC11056897. https://doi.org/10.4254/wjh.v16.i4.511
  5. Huang DQ, Wong VWS., Rinella ME, Boursier J, Lazarus JV, Yki-Jarvinen H, Loomba R. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11(1):14. PMID: 40050362. https://doi.org/10.1038/s41572-025-00599-1
  6. Pecani M, Andreozzi P, Cangemi R, Corica B, Miglionico M, Romiti GF et al. Metabolic syndrome and liver disease: Re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD. J Clin Med. 2025;14(8):2750. PMID: 40283580. PMCID: PMC12028215. https://doi.org/10.3390/jcm14082750
  7. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80(5):694–701. PMID: 38286339. https://doi.org/10.1016/j.jhep.2024.01.014
  8. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–700. PMID: 35587339. https://doi.org/10.1210/clinem/dgac321
  9. Sangro P, de la Torre Alaez M, Sangro B, D’Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): An update of the recent advances in pharmacological treatment. J Physiol Biochem. 2023;79(4):869–79. PMID: 36976456. PMCID: PMC10635944. https://doi.org/10.1007/s13105-023-00954-4
  10. Евстифеева С.Е., Шальнова С.А., Куценко В.А., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. с соавт. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):40–49. [Evstifeeva SE, Shalnova SA, Kutsenko VA, Yarovaya EV, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: Associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022;21(9):40–49 (In Russ.)]. EDN: SITSBL. https://doi.org/10.15829/1728-8800-2022-3356
  11. Драпкина О.М., Евстифеева С.Е., Шальнова С.А., Куценко В.А., Баланова Ю.А., Имаева А.Э. с соавт. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025;24(2):6–16. [Drapkina OM, Evstifeeva SE, Shalnova SA, Kutsenko VA, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(2):6–16 (In Russ.)]. EDN: CVQNXA. https://doi.org/10.15829/1728-8800-2025-4316
  12. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3–10. PMID: 37940495. https://doi.org/10.1016/j.ejim.2023.11.005
  13. Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z et al. Liver diseases: Epidemiology, causes, trends and predictions. Signal Transduct Target Ther. 2025;10(1):33. PMID: 39904973. PMCID: PMC11794951. https://doi.org/10.1038/s41392-024-02072-z
  14. Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773–91. PMID: 37204656. PMCID: PMC10198034. https://doi.org/10.1007/s12072-023-10543-8
  15. Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1):101506. PMID: 38141808. https://doi.org/10.1016/j.diabet.2023.101506
  16. Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9(2):159–69. PMID: 38215780. https://doi.org/10.1016/S2468-1253(23)00275-3
  17. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13. PMID: 34555346. https://doi.org/10.1016/S2468-1253(21)00308-3
  18. Roderburg C, Krieg S, Krieg A, Vaghiri S, Mohr R, Konrad M et al. Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: A retrospective analysis of 173,966 patients. Clin Res Cardiol. 2023;112(10):1446–53. PMID: 37410163. PMCID: PMC10562311. https://doi.org/10.1007/s00392-023-02250-z
  19. Cho EJ, Chung GE, Yoo JJ, Cho Y, Lee KN, Shin DW et al. Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups. Cardiovasc Diabetol. 2024;23(1):340. PMID: 39267090. PMCID: PMC11395983. https://doi.org/10.1186/s12933-024-02408-7
  20. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis. Gut. 2022;71(1):156–62. PMID: 33303564. https://doi.org/10.1136/gutjnl-2020-323082
  21. Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies. Gut. 2022;71(4):778–88. PMID: 33685968. https://doi.org/10.1136/gutjnl-2021-324191.
  22. Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683–98. PMID: 40802944. https://doi.org/10.1056/NEJMra2412865
  23. Филиппова Л. П., Белобородова Э.И., Белобородова Е.В., Алексеева А.С., Шепелева Е.Г. Качество жизни больных циррозом печени в зависимости от тонуса вегетативной нервной системы. Бюллетень сибирской медицины. 2012;11(4):152–157. [Filippova LP, Beloborodova EI, Beloborodova YeV, Alekseyeva AS, Shepeleva YeG. Quality of life in patients with liver cirrhosis on the tone of vegetative nervous system. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2012;11(4):152–157 (In Russ.)]. EDN: PEJIZX. https://doi.org/10.20538/1682-0363-2012-4-152-157
  24. Приходько В.А., Оковитый С.В. Психоневрологические нарушения при неалкогольной жировой болезни печени. Терапия. 2022;8(7):64–77. [Prikhodko VA, Okovity SV. Psychoneurological disorders in non-alcoholic fatty liver disease. Terapiya = Therapy 2022;8(7):64–77 (In Russ.)]. EDN: OQXJFZ. https://dx.doi.org/10.18565/therapy.2022.7.64-77
  25. Revicki DA, Kleinman L, Cella D. A history of health-related quality of life outcomes in psychiatry. Dialogues Clin Neurosci. 2014;16(2):127–35. PMID: 25152652. PMCID: PMC4140507. https://doi.org/10.31887/DCNS.2014.16.2/drevicki
  26. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual Life Outcomes. 2006;4:79. PMID: 17034633. PMCID: PMC1629006. https://doi.org/10.1186/1477-7525-4-79
  27. Sitlinger A, Zafar SY. Health-related quality of life: The impact on morbidity and mortality. Surg Oncol Clin N Am. 2018;27(4):675–84. PMID: 30213412. PMCID: PMC6428416. https://doi.org/10.1016/j.soc.2018.05.008
  28. Klak A, Minko M, Siwczynska D, Samolinski B. Selected questionnaire methods studying the quality of life. Postepy Dermatol Alergol. 2015;32(3):210–15. PMID: 26161063. PMCID: PMC4495113. https://doi.org/10.5114/pdia.2015.48047
  29. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300. PMID: 10403745. PMCID: PMC1727607. https://doi.org/10.1136/gut.45.2.295
  30. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(10):2093–100.e3. PMID: 30639779. https://doi.org/10.1016/j.cgh.2019.01.001
  31. Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1): e000106. PMID: 27648297. PMCID: PMC5013331. https://doi.org/10.1136/bmjgast-2016-000106.
  32. Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, Younossi ZM. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health-Related Quality of Life (HRQOL) Health Qual Life Outcomes. 2016;14:18. PMID: 26860700. PMCID: PMC4746896. https://doi.org/10.1186/s12955-016-0420-z
  33. Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res. 2018;112:73–80. PMID: 30097139. https://doi.org/10.1016/j.jpsychores.2018.07.004
  34. Lv K, Zhou R, Gu Y, Kong T, Chen Y, Shao Y et al. Status and factors influencing health-related quality of life in patients with non-alcoholic fatty liver disease in Hangzhou: A cross-sectional study. BMJ Open 2025;15(3):e088357. PMID: 40044211. PMCID: PMC11883542. https://doi.org/10.1136/bmjopen-2024-088357
  35. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017;37(8):1209–18. PMID: 28211165. https://doi.org/10.1111/liv.13391
  36. Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018. Liver Int. 2022;42(12):2646–61. PMID: 36161464. https://doi.org/10.1111/liv.15437
  37. Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-Gomez M, Yilmaz Y, Keklikkiran C et al.; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024;6(7):101066. PMID: 39022387 PMCID: PMC11252535. https://doi.org/10.1016/j.jhepr.2024.101066. Erratum in: JHEP Rep. 2025;7(3):101359. PMID: 39022387. https://doi.org/10.1016/j.jhepr.2025.101359
  38. Astrom H, Shang Y, Hagstrom H, Wester A. Persons with metabolic dysfunction-associated steatotic liver disease are at increased risk of severe depression. Liver Int. 2024;44(10):2551–63. PMID: 38949395. https://doi.org/10.1111/liv.16019
  39. Funuyet-Salas J, Perez-San-Gregorio MA, Martín-Rodríguez A, Romero-Gomez M. Quality of life and coping in nonalcoholic fatty liver disease: Influence of diabetes and obesity. Int J Environ Res Public Health. 2021;18(7):3503. PMID: 33800585. PMCID: PMC8036804. https://doi.org/10.3390/ijerph18073503
  40. Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterol. 2016;3(1):e000069. PMID: 27110379. PMCID: PMC4838661. https://doi.org/10.1136/bmjgast-2015-000069
  41. Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085–92.e1. PMID: 30580090. https://doi.org/10.1016/j.cgh.2018.12.016
  42. Jamali R, Veisi S, Jamali A, Yaseri M. Relationship between cardiovascular disease risk factors and quality of life in patients with metabolic-associated fatty liver disease. Hepat Mon. 2022;22(1):e124229. https://doi.org/10.5812/hepatmon-124229
  43. Puneem US, Nagasubramanian VR, Sindgi VM, Rajendran Ramakrishnan SM, Pelluri R. Health-related quality of life and its determinants among South Indian type 2 diabetes patients with and without non-alcoholic fatty liver disease. Egypt Liver Journal. 2023;13(57):1–8. https://doi.org/10.1186/s43066-023-00288-2
  44. Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: A systematic review and meta-analysis of observational studies. J Hypertens. 2011;29(2):179–88. PMID: 21045726. https://doi.org/10.1097/HJH.0b013e328340d76f
  45. Goldenberg M, Danovitch I, IsHak WW. Quality of life and smoking. Am J Addict. 2014;23(6):540–62. PMID: 25255868. https://doi.org/10.1111/j.1521-0391.2014.12148.x
  46. Papatheodoridi M, Pallini G, Aithal G, Lim HK, Cobbold J, Plaz Torres MC et al. Health-related quality of life in patients with nonalcoholic fatty liver disease: A prospective multi-center UK Study. Clin Gastroenterol Hepatol. 2023;21(12):3107–14.e3. PMID: 37880933. https://doi.org/10.1016/j.cgh.2023.04.018
  47. McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternent L et al. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep. 2020;2(3):100099. PMID: 32435754. PMCID: PMC7229498. https://doi.org/10.1016/j.jhepr.2020.100099
  48. Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, Jones DE. Health related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61(5):1158–65. PMID: 25010259. https://doi.org/10.1016/j.jhep.2014.06.034
  49. Nunes MI. The relationship between quality of life and adherence to treatment. Curr Hypertens Rep. 2001;3(6):462–65. PMID: 11734090. https://doi.org/10.1007/s11906-001-0007-9
  50. Uchmanowicz B, Chudiak A, Mazur G. The influence of quality of life on the level of adherence to therapeutic recommendations among elderly hypertensive patients. Patient Prefer Adherence. 2018;12:2593–603. PMID: 30584283. PMCID: PMC6287422. https://doi.org/10.2147/PPA.S182172
  51. Funuyet-Salas J, Perez-San-Gregorio MA, Martín-Rodríguez A, Romero-Gomez M. Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study. J Psychosom Res. 2022;162:111045. PMID: 36174369. https://doi.org/10.1016/j.jpsychores.2022.111045
  52. Serfaty L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int. 2018;38 Suppl 1:52–55. PMID: 29427486. https://doi.org/10.1111/liv.13637
  53. Ивашкин В.Т., Драпкина О.М., Маевская М.В., Райхельсон К.Л., Оковитый С.В., Жаркова М.С. с соавт. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского общества профилактики неинфекционных заболеваний, Российской ассоциации эндокринологов, Российского научного медицинского общества терапевтов, Национального общества профилактической кардиологии, Российской ассоциации геронтологов и гериатров по неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2025;35(1):94–152. [Ivashkin VT, Drapkina OM, Maevskaya MV, Raikhelson KL, Okovityi SV, Zharkova MS et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on non-alcoholic fatty liver disease. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2025;35(1):94–152 (In Russ.)]. EDN: HLXIGH. https://doi.org/10.22416/1382-4376-2025-35-1-94-152
  54. Stine JG, DiJoseph K, Pattison Z, Harrington A, Chinchilli VM, Schmitz KH, Loomba R. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Am J Gastroenterol. 2022;118(7):1204–13. PMID: 36705333. PMCID: PMC10287833. https://doi.org/10.14309/ajg.0000000000002098
  55. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46. PMID: 28545937. https://doi.org/10.1016/j.jhep.2017.05.016
  56. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2019;1(6):468–79. PMID: 32039399. PMCID: PMC7005657. https://doi.org/10.1016/j.jhepr.2019.10.008
  57. Middleton KR, Anton SD, Perri MG. Long-term adherence to health behavior change. Am J Lifestyle Med. 2013;7(6):395–404. PMID: 27547170. PMCID: PMC4988401. https://doi.org/10.1177/1559827613488867
  58. Alkhouri N, Edwards K, Berman M, Finn H, Escandon R, Lupinacci P et al. Novel prescription digital therapeutic option for the treatment of metabolic dysfunction-associated steatotic liver disease. Gastro Hep Adv. 2023;3(1):9–16. PMID: 39132187. PMCID: PMC11307699. https://doi.org/10.1016/j.gastha.2023.08.019
  59. Yang X, Li Z, Sun J. Effects of cognitive behavioral therapy–based intervention on improving glycaemic, psychological, and physiological outcomes in adult patients with diabetes mellitus: A meta-analysis of randomized controlled trials. Front Psychiatry. 2020;11:711. PMID: 32848906. PMCID: PMC7399630. https://doi.org/10.3389/fpsyt.2020.00711
  60. Garcia-Silva J, Borrego IRS, Navarrete NN, Peralta-Ramirez MI, Aguila FJ, Caballo VE. Efficacy of cognitive-behavioural therapy for lifestyle modification in metabolic syndrome: A randomised controlled trial with a 18-months follow-up. Psychol Health. 2024;39(2):195–215. PMID: 35345950. https://doi.org/10.1080/08870446.2022.2055023
  61. Mendys P, Zullig LL, Burkholder R, Granger BB, Bosworth HB. Medication adherence: Process for implementation. Patient Prefer Adherence. 2014;8:1025–34. PMID: 25114513. PMCID: PMC4122551. https://doi.org/ 10.2147/PPA.S65041
  62. Hayward KL, Weersink RA. Improving medication-related outcomes in chronic liver disease. Hepatol Commun. 2020;4(11):1562–77. PMID: 33163829. PMCID: PMC7603526. https://doi.org/10.1002/hep4.1612
  63. Лазебник Л.Б., Голованова Е.В., Туркина С.В., Райхельсон К.Л., Оковитый С.В., Драпкина О.М. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1):4–52. [Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovityy SV, Drapkina OM et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021;185(1):4–52 (In Russ.)]. EDN: KJLOJV. https://doi.org/ 10.31146/1682-8658-ecg-185-1-4-52
  64. Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 2022;20(6):1354–61.e7. PMID: 34329774. https://doi.jrg/10.1016/j.cgh.2021.07.039
  65. Лазебник Л.Б., Туркина С.В., Голованова Е.В. Целевое применение гепатопротекторов для лечения различных стадий неалкогольной жировой болезни печени (жировой дегенерации печени по МКБ 10) и ассоциированных коморбидных состояний; таблицы для врачебного пользования. Экспериментальная и клиническая гастроэнтерология. 2024;(10):11–35. [Lazebnik LB, Turkina SV, Golovanova EV. Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; Tables for medical use. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2024;(10):11–35 (In Russ.)]. EDN: RFVRUV. https://doi.org/10.31146/1682-8658-ecg-230-10-11-35
  66. Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019;6(1):e000307. PMID: 31523440. PMCID: PMC6711446. https://doi/org/10.1136/bmjgast-2019-000307
  67. Stefan N, Hartleb M, Popovic B, Varona R. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: Study protocol of a randomized, double-blind, phase IV clinical trial. Trials 2024;25(1):374. PMID: 38858768. PMCID: PMC11165850. https://doi.org/10.1186/s13063-024-08208-4
  68. The Liver Meeting: San Diego, California, Nov 15–19, 2024. Hepatology. 2024;80(S1):S1–S2011. PMID: 39730189. https://doi.org/10.1097/HEP.0000000000001077

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. The effect of taking essential phospholipids on the severity of liver steatosis according to the controlled parameter of ultrasound attenuation in patients with metabolically associated fatty liver disease [68]

Жүктеу (98KB)
Метадеректер
3. 2. The effect of taking essential phospholipids on the overall assessment of health-related quality of life in patients with metabolically associated fatty liver disease [68]

Жүктеу (78KB)
Метадеректер
4. Ris. 3. The effect of taking essential phospholipids!EV for 5ITLHS:mortality in patients with metabolically associated J1 fatty liver disease [68]

Жүктеу (64KB)
Метадеректер

© Bionika Media, 2025